Abstract
An Observational Chart Review of a Comparison of Generic to Reference Liposome-Encapsulated Doxorubicin Hydrochloride in Subjects with Epithelial Ovarian Carcinoma Who Have Failed Platinum-Based Chemotherapy
Highlights
Ovarian Cancer is the 9th most common cancer among women
This study tested for the effects of generic liposome-encapsulated doxorubicin hydrochloride compared to reference-pegylated liposomal doxorubicin hydrochloride as a treatment for patients afflicted with epithelial ovarian carcinoma whose disease has progressed after platinum-based chemotherapy
Chart-reviews of actual patients enrolled in a community-based NIH trial suggest that both generic and reference liposomal doxorubicin hydrochloride (HCl) are effective as treatment for ovarian cancer carcinoma
Summary
Ovarian Cancer is the 9th most common cancer among women. It ranks 5th in cancer deaths and accounts for more deaths than any other cancer of the female reproductive system [1]. In 70% of cases, the diagnosis is often delayed till the disease is far advanced. Five year relative survival rates show dramatic decreased survival from 71.7% to 27.4% in far advanced disease (Figure 1) [2]. These ovarian carcinomas develop mainly in women that are 60 years of age or older [3]. White women have been found to have higher incidence and mortality [4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
